RT Journal Article
T1 Prognostic microRNAs in upper tract urothelial carcinoma: multicenter and international validation study.
A1 Izquierdo, Laura
A1 Montalbo, Ruth
A1 Ingelmo-Torres, Mercedes
A1 Mallofré, Carme
A1 Ramírez-Backhaus, Miguel
A1 Rubio, Jose
A1 Van der Heijden, Antoine G
A1 Schaafsma, Ewout
A1 Lopez-Beltran, Antonio
A1 Blanca, Ana
A1 Lawrentschuk, Nathan
A1 Alcaraz, Antonio
A1 Mengual, Lourdes
K1 microRNAs
K1 prognosis
K1 upper tract urothelial carcinoma
AB To validate previously discovered miRNAs (miR-31-5p and miR-149-5p) as prognostic factors for UTUC in an independent cohort of UTUC patients. Multicenter, international and retrospective study of formalin-fixed paraffin-embedded tissue samples from 103 UTUC patients (45 progressing and 58 non-progressing) who underwent radical nephroureterectomy. Total RNA was isolated and reverse transcribed. The expression of target miRNAs (miR-31-5p and miR-149-5p) and the endogenous control miR-218-5p was evaluated in all samples by reverse transcription quantitative PCR. Normalized miRNA expression values were evaluated by multivariate forward stepwise Cox regression analysis. Kaplan Meier curves were used to discriminate between two groups of patients with a different probability of tumour progression. The mean age (range) of the series was 67 (33-94) years. Overall, 45 patients (43.7%) developed tumour progression and 32 patients (31.2%) died, 20 of these (62.5%) due to their UTUC, after a median follow-up of 36 months. The mean time for tumour progression and cancer-specific survival were 15 and 20 months, respectively. Five year tumour progression free survival and cancer-specific survival were 58% for ≤ pT2, 36% for pT3 and 0% for pT4 and 67.8% for ≤ pT2, 50.6% for pT3 and 0% for pT4, respectively. In the multivariate analysis, expression of miR-31-5p was found to be an independent prognostic factor of tumour progression (HR 1.1; 95% CI 1.039-1.273; p=0.02). Kaplan Meier curve shows that miR-31-5p expression values are able to discriminate between two groups of UTUC patients with a different probability of tumour progression (p=0.007). We have been able to validate our previous results in an independent multicentre international cohort of UTUC patients, suggesting that miRNA-31-5p could be a useful prognostic marker of UTUC progression. The application of miRNA expression values to clinical practice could refine the currently used clinicopathological-based approach for predicting UTUC patients' outcome.
YR 2017
FD 2017-05-16
LK https://hdl.handle.net/10668/25133
UL https://hdl.handle.net/10668/25133
LA en
DS RISalud
RD Apr 11, 2025